TriangleIvonescimab (NCT07405190)
Ivonescimab trial for Lung Cancer (NSCLC) (NCT07405190). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced nonsquamous lung cancer after targeted therapy. Eligible alterations are classical EGFR mutations or ALK, ROS1, RET, or NTRK fusions.
The idea: ivonescimab targets the PD1 immune brake and VEGFA blood-vessel signal. After platinum/pemetrexed, patients receive ivonescimab alone. Chemotherapy-naive patients without EGFR mutations receive ivonescimab plus carboplatin/pemetrexed for four cycles, then ivonescimab/pemetrexed if disease remains controlled. Infusions occur every three weeks, for up to two years. Researchers measure response and safety.
This phase 2 study plans 46 patients. Massachusetts General Hospital sponsors; two Boston US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.